Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924381 | 1.00 | MAPT (0.47) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL27965768 | 1.00 | MAPT (0.47) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL19441886 | 0.91 | GPR119 (0.42) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL29731850 | 0.87 | GPR119 (0.50) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL29741983 | 0.87 | GPR119 (0.50) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL22802474 | 0.87 | GPR119 (0.50) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL14924375 | 0.87 | GPR119 (0.50) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL30512281 | 0.87 | GPR119 (0.50) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL14925849 | 0.87 | GPR119 (0.50) | MAPTALDH1A1LMNAGPR119MET | |
| SCHEMBL14914399 | 0.86 | CHRNB2 (0.47) | MAPTALDH1A1LMNARAB9ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | MAPT 2050/4885ALDH1A1 4561/4885LMNA 2651/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | MAPT 2050/4885ALDH1A1 4561/4885LMNA 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.